Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Treg-enriched donor cells
- Development stage
- Phase 1
- Lead developer
- Dana-Farber Cancer Institute
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Treg-enriched donor cells (Dana-Farber) is an experimental cellular therapy developed by the Dana-Farber Cancer Institute for patients with relapsed/refractory or ultra-high-risk acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). This therapy is a central component of an "immunosuppression-free" (IS-free) haploidentical hematopoietic cell transplantation (HCT) protocol. The process involves the ex vivo enrichment of regulatory T cells (Tregs) from a haploidentical (half-matched) related donor. These Tregs are infused into the patient to suppress graft-versus-host disease (GvHD) by modulating the immune response, which allows for the co-infusion of unmodified donor T cells that provide a potent graft-versus-leukemia (GvL) effect. This approach aims to eliminate the need for post-transplant pharmacological immunosuppression. The protocol also includes conditioning with chemotherapy and targeted radiation, such as Total Myeloid and Lymphoid Irradiation (TMLI).
- Other names
- IS-free Treg-cell graft-engineered haplo transplantTreg-enriched donor cells
Beyond the preview
Go deeper on Treg-enriched donor cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Treg-enriched donor cells.